Post on 17-Dec-2015
transcript
Anchored Periplasmic Expression (APEx)
A Powerful Technology for Antibody Discovery and Combinatorial Protein Library Screening
George Georgiou, Dept. of Chemical Eng., Biomedical Eng., Molecular Genetics and
Microbiology and ICMB
Brent L. Iverson, Dept. of Chemistry and Biochemistry, ICMB
APEx opportunities
Non-exclusive licensing available SRA/partnerships for in-house (UT) Ab
development Start-up opportunities for specific
therapeutic fields Commercial status:
• Non-exclusive licenses (therapeutic Ab)
• >$ 1.5 million in royalties from the pharmaceutical industry since 2004
IP status: 2 U.S. patents issued, 3 pending
The APEx platform: fields of use
Antibody discovery Identifying protein:protein interactions
(quantitative) Protein expression maturation Enzyme discovery yes, for hydrolytic
enzymes Discovery of cell internalization/organ
targeting peptides yes
The APEx platform: other features
Freedom to operate in combinatorial protein screening
Quantitative results Employs bacteria and hence technically
facile
APEx: the core technologySpheroplasting
Receptor
Harvey et al., Proc. Natl. Acad. Sci. 101:9193 (2004)
Receptor+
APEx: technology validation
Engineering of antibodies that bind to the anthrax toxin with half-lives >20 hours; proven effective for anthrax prophylaxis and therapy
Engineering of high-affinity diagnostic Ab to methamphetamine
Engineering of Ab exhibiting markedly increased expression yield
Isolation of interacting proteins from libraries => quantitative 2-hybrid screening